Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ...

PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...

CABA-201, an investigational therapy by Cabaletta Bio, Inc. has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as a possible treatment for lupus and lupus nephritis ...

Initial Phase 1 of 2 RESET-Myositis and RESET-SLE clinical trial data of the investigational therapy, CABA-201, revealed positive outcomes. The first two study participants did not exhibit infections ...

The NASDAQ 100 Pre-Market Indicator is up 57.92 to 21,393.74. The total Pre-Market volume is currently 272,014,558 shares traded.The following are the most active stocks for the pre-market session ...